April 14, 2021
Business News

Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand

MUMBAI, India & REYKJAVIK, Iceland–()–Gulf FZ LCC (“Cipla Gulf’), subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” and biopharmaceutical company Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.

The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Resumen: Smiths Detection confirma que BioFlash es capaz de detectar la COVID-19 en el aire
Africa’s Best Corporate-Startup Collaboration Accelerator, Startupbootcamp AfriTech, Now Open for Applications from the Most Disruptive Startups
Minnesota Department of Transportation Leverages Iteris’ ClearMobility Cloud for Improved Statewide Mobility